Department of Urology, Heilongjiang Provincial Hospital, Heilongjiang Provincial Hospital, Harbin Institute of Technology, Harbin, 150036, China.
Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, No.37 Yiyuan Street, Nangang District, Harbin, 150001, Heilongjiang, China.
Sci Rep. 2024 Oct 30;14(1):26156. doi: 10.1038/s41598-024-77638-6.
Renal clear cell cancer (RCC) is a complex disease that is challenging to predict patient outcomes. Despite improvements with targeted therapy, personalized treatment planning is still needed. Artificial intelligence (AI) can help address this challenge by developing predictive models that accurately forecast patient survival periods. With AI-powered decision support, clinicians can provide patients with tailored treatment plans, enhancing treatment efficacy and quality of life. The study analyzed 267 patients with renal clear cell carcinoma, focusing on 26 who received targeted drug therapy. The data was refined by excluding 8 patients without enhanced CT scans. The research team categorized patients into two groups based on their expected lifespan: Group 1 (over 3 years) and Group 2 (under 3 years). The UPerNet algorithm was used to extract features from CT tumor markers, validating their effectiveness. These features were then used to develop an AI-based predictive model trained on the dataset. The developed AI model demonstrated remarkable accuracy, achieving a rate of 93.66% in Group 1 and 94.14% in Group 2. In conclusion, our study demonstrates the potential of AI technology in predicting the survival time of RCC patients undergoing targeted drug therapy. The established prediction model exhibits high predictive accuracy and stability, serving as a valuable tool for clinicians to facilitate the development of more personalized treatment plans for patients. This study highlights the importance of integrating AI technology in clinical decision-making, enabling patients to receive more effective and targeted treatment plans that enhance their overall quality of life.
肾透明细胞癌（RCC）是一种复杂的疾病，预测患者预后具有挑战性。尽管靶向治疗有所改善，但仍需要个性化的治疗计划。人工智能（AI）可以通过开发准确预测患者生存周期的预测模型来帮助应对这一挑战。通过 AI 驱动的决策支持，临床医生可以为患者提供量身定制的治疗计划，提高治疗效果和生活质量。该研究分析了 267 名肾透明细胞癌患者，重点关注接受靶向药物治疗的 26 名患者。通过排除 8 名没有增强 CT 扫描的患者，对数据进行了细化。研究团队根据患者的预期寿命将患者分为两组：组 1（超过 3 年）和组 2（低于 3 年）。使用 UPerNet 算法从 CT 肿瘤标志物中提取特征，验证其有效性。然后，这些特征被用于在数据集上开发基于 AI 的预测模型。开发的 AI 模型表现出出色的准确性，在组 1 中的准确率为 93.66%，在组 2 中的准确率为 94.14%。总之，我们的研究表明 AI 技术在预测接受靶向药物治疗的 RCC 患者生存时间方面具有潜力。建立的预测模型具有较高的预测准确性和稳定性，是临床医生为患者制定更个性化治疗计划的有价值工具。这项研究强调了在临床决策中整合 AI 技术的重要性，使患者能够接受更有效和有针对性的治疗计划，从而提高他们的整体生活质量。
